Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420314 · ClinicalTrials.gov registry record · Phase 2
Pharmacological Ascorbate for Lung Cancer
A Phase 2 study, sponsored by Joseph J. Cullen, MD, FACS.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT02420314: Completed Phase 2 study, sponsored by Joseph J. Cullen, MD, FACS.
NCT02420314 is a Phase 2 study that has completed, run by Joseph J. Cullen, MD, FACS. The registered enrollment target is 55 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02420314, a Phase 2 study, has completed, sponsored by Joseph J. Cullen, MD, FACS.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of non-small cell lung cancer (NSCLC) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.
Primary Outcome
From cycle 1, day 1, to documented disease progression in CT imaging as described by RECIST criteria
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-04 |
| Est. Completion | 2022-08-27 |
| Phase | Phase 2 |
What the finished NCT02420314 record still lists
NCT02420314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02420314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02420314 about?
NCT02420314 is a clinical study titled "Pharmacological Ascorbate for Lung Cancer". This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of non-small cell lung cancer (NSCLC) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.
What is the current status of trial NCT02420314?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2015-04. Estimated completion is 2022-08-27.
What interventions are being tested in trial NCT02420314?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT02420314?
This trial is sponsored by Joseph J. Cullen, MD, FACS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02420314's enrollment target sits among peer trials
55 1153rd of 2000 higher than 841 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia